

David C Fisher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/916869/publications.pdf>

Version: 2024-02-01

58
papers

1,862
citations

430874

18
h-index

276875

41
g-index

58
all docs

58
docs citations

58
times ranked

3836
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.	1.6	339
2	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016, 128, 195-203.	1.4	259
3	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	16.8	227
4	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , 2019, 134, 22-29.	1.4	129
5	Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1b study. <i>Lancet Haematology</i> , 2019, 6, e38-e47.	4.6	98
6	High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	92
7	Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6157-E6165.	7.1	90
8	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e419-e428.	4.6	60
9	Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. <i>Lancet Oncology</i> , 2021, 22, 1391-1402.	10.7	53
10	A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 89-95.	2.5	51
11	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. <i>Blood Advances</i> , 2021, 5, 5098-5106.	5.2	46
12	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.	5.2	40
13	Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab. <i>Clinical Cancer Research</i> , 2014, 20, 3310-3318.	7.0	29
14	Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. <i>Blood</i> , 2022, 139, 686-689.	1.4	29
15	Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. , 2017, 5, 67.		28
16	The Combination of Duvelisib, a PI3K- γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts. <i>Blood</i> , 2018, 132, 683-683.	1.4	28
17	Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 32-32.	1.4	28
18	Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. <i>European Journal of Cancer</i> , 2021, 148, 411-421.	2.8	27

#	ARTICLE	IF	CITATIONS
19	A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. <i>Leukemia</i> , 2021, 35, 1064-1072.	7.2	25
20	Targeting constitutively active <scp>STAT3</scp> in chronic lymphocytic leukemia: A clinical trial of the <scp>STAT3</scp> inhibitor pyrimethamine with pharmacodynamic analyses. <i>American Journal of Hematology</i> , 2021, 96, E95-E98.	4.1	17
21	Updated Safety and Efficacy Results from a Phase 2 Study of Acabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 20-21.	1.4	16
22	Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. <i>Blood</i> , 2016, 128, 3243-3243.	1.4	15
23	Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial. <i>Blood</i> , 2013, 122, 3062-3062.	1.4	14
24	A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, , .	7.2	14
25	Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome. <i>Blood</i> , 2020, 136, 46-47.	1.4	13
26	Histopathologic spectrum of hypersensitivity reactions associated with anti-CD52 therapy (alemtuzumab). <i>Journal of Cutaneous Pathology</i> , 2016, 43, 989-993.	1.3	10
27	TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. <i>Blood</i> , 2016, 128, 641-641.	1.4	10
28	Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL. <i>Blood</i> , 2015, 126, 4158-4158.	1.4	9
29	Perioperative Serum 25-Hydroxyvitamin D Levels as a Predictor of Postoperative Opioid Use and Opioid Use Disorder: a Cohort Study. <i>Journal of General Internal Medicine</i> , 2020, 35, 2545-2552.	2.6	7
30	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10.	1.2	7
31	A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL. <i>Blood</i> , 2019, 134, 1763-1763.	1.4	6
32	Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma.. <i>Blood</i> , 2007, 110, 2331-2331.	1.4	6
33	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018, 132, 145-145.	1.4	5
34	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.	1.4	4
35	Thyroid lymphoma on a background of Hashimoto's thyroiditis: PET/CT appearances. <i>Clinical Imaging</i> , 2014, 38, 864-867.	1.5	3
36	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1312-1315.	1.3	3

#	ARTICLE	IF	CITATIONS
37	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 706-706.	1.4	3
38	Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2011, 118, 1635-1635.	1.4	3
39	Obatoclox in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL. <i>Blood</i> , 2011, 118, 2865-2865.	1.4	3
40	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 522-522.	1.4	3
41	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 1650-1650.	1.4	2
42	A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.. <i>Blood</i> , 2007, 110, 1358-1358.	1.4	2
43	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4496-4496.	1.4	2
44	Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3156-3156.	1.4	2
45	Unusual Presentations of Malignancy. <i>Journal of Clinical Oncology</i> , 2001, 19, 3291-3293.	1.6	1
46	A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed By Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL. <i>Blood</i> , 2015, 126, 4159-4159.	1.4	1
47	T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development. <i>Blood</i> , 2016, 128, 3015-3015.	1.4	1
48	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. <i>Blood</i> , 2020, 136, 37-38.	1.4	1
49	Topical tofacitinib for the management of lymphocyticâ€variant hypereosinophilic syndrome with cutaneous involvement. <i>Dermatologic Therapy</i> , 2022, 35, e15518.	1.7	1
50	Reply to J. Mehta. <i>Journal of Clinical Oncology</i> , 2009, 27, e139-e140.	1.6	0
51	SCDT-26. STEM CELL LOADED ONCOLYTIC VIRUSES TRACK AND KILL METASTATIC BRAIN TUMORS. <i>Neuro-Oncology</i> , 2017, 19, vi270-vi270.	1.2	0
52	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. <i>Blood</i> , 2004, 104, 1227-1227.	1.4	0
53	Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD.. <i>Blood</i> , 2004, 104, 3317-3317.	1.4	0
54	Non-Myeloablative Allogeneic Transplantation for Hodgkinâ€™s and Non-Hodgkinâ€™s Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. <i>Blood</i> , 2007, 110, 3041-3041.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,. Blood, 2011, 118, 3716-3716.	1.4	0
56	Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. Blood, 2012, 120, 1980-1980.	1.4	0
57	B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development. Blood, 2015, 126, 4001-4001.	1.4	0
58	Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study. Blood, 2018, 132, 1646-1646.	1.4	0